
Supreme Court, Mifepristone: Trump Faces Stance Test
Legal challenges surrounding the abortion drug mifepristone have brought the issue back to the Supreme Court, creating political pressure on Donald Trump. A recent ruling from the 5th Circuit Court of Appeals mandated in-person visits for drug access, a development anti-abortion advocates view as a major win. The Trump administration has responded by focusing on procedural legal challenges and citing an ongoing FDA review to delay definitive rulings. Critics argue that the administration's silence is politically risky, while legal experts suggest the administration will soon be forced to take a clear public stance on the drug's regulation.






















